PARP1 and ovarian carcinoma: Given the complexity of selecting PARP inhibitors for ovarian cancer patients, we propose a decision-making framework (Fig. 3) for newly diagnosed advanced EOC and platinum-sensitive EOC, based on evidence from Phase 3 randomised trials, to aid clinicians in understanding PARP inhibitor efficacy.